Synthesis of a heterotrifunctional linker for the site-specific preparation of antibody-drug conjugates with two distinct warheads.

Codelivery of multiple therapeutic agents with different anticancer mechanisms can overcome drug resistance as well as generate additive or synergistic anticancer effects that may enhance the antitumor efficacy. Antibody-drug conjugates (ADCs) can be used for highly specific delivery of multiple therapeutic agents with different anticancer mechanisms, though more research is required towards designing flexible platforms on which dual drug ADCs could be prepared. Herein, we describe the synthesis of a heterotrifunctional linker that could be used to construct flexible platforms for preparing dual-cytotoxic drug conjugates in a site-specific manner. As a proof of concept, we synthesized dual drug ADCs carrying monomethyl auristain E (MMAE, tubulin polymerization inhibitor) and pyrrolobenzodiazepine dimer (PBD, DNA minor groove alkylator). We then evaluated the dual drug ADCs for in vitro efficacy and confirmed the dual mechanism of action.

[1]  M. Distefano,et al.  Application of meta‐ and para‐Phenylenediamine as Enhanced Oxime Ligation Catalysts for Protein Labeling, PEGylation, Immobilization, and Release , 2015, Current protocols in protein science.

[2]  J. Reichert,et al.  Antibody-drug conjugates , 2013, mAbs.

[3]  W. Olson,et al.  In Vitro and In Vivo Responses of Advanced Prostate Tumors to PSMA ADC, an Auristatin-Conjugated Antibody to Prostate-Specific Membrane Antigen , 2011, Molecular Cancer Therapeutics.

[4]  K. Ulbrich,et al.  Simultaneous delivery of doxorubicin and gemcitabine to tumors in vivo using prototypic polymeric drug carriers. , 2009, Biomaterials.

[5]  J. Connors,et al.  Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study. , 2013, The Lancet. Oncology.

[6]  M. Liedtke,et al.  Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia. , 2016, The New England journal of medicine.

[7]  Herren Wu,et al.  Efficient Preparation of Site-Specific Antibody-Drug Conjugates Using Cysteine Insertion. , 2017, Molecular pharmaceutics.

[8]  J. Mackey,et al.  PTEN Loss Is Associated with Worse Outcome in HER2-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance , 2015, Clinical Cancer Research.

[9]  Herren Wu,et al.  Hydrolytically Stable Site-Specific Conjugation at the N-Terminus of an Engineered Antibody. , 2015, Bioconjugate chemistry.

[10]  Paul Polakis,et al.  Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index , 2008, Nature Biotechnology.

[11]  Julie Zhang,et al.  A monomethyl auristatin E-conjugated antibody to guanylyl cyclase C is cytotoxic to target-expressing cells in vitro and in vivo , 2018, PloS one.

[12]  C. Fegan,et al.  Fludarabine-mediated suppression of the excision repair enzyme ERCC1 contributes to the cytotoxic synergy with the DNA minor groove crosslinking agent SJG-136 (NSC 694501) in chronic lymphocytic leukaemia cells , 2007, British Journal of Cancer.

[13]  P. Burke,et al.  Optimization of a PEGylated Glucuronide-Monomethylauristatin E Linker for Antibody–Drug Conjugates , 2016, Molecular Cancer Therapeutics.

[14]  Eric T. Kool,et al.  Oximes and Hydrazones in Bioconjugation: Mechanism and Catalysis. , 2017, Chemical reviews.

[15]  M. Goldenberg.  Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. , 1999, Clinical therapeutics.

[16]  S. Slovin,et al.  Chemotherapy and immunotherapy combination in advanced prostate cancer. , 2012, Clinical advances in hematology & oncology : H&O.

[17]  J. Lehár,et al.  Synergistic drug combinations improve therapeutic selectivity , 2009, Nature Biotechnology.

[18]  Herren Wu,et al.  Stabilization of cysteine-linked antibody drug conjugates with N-aryl maleimides. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[19]  Frank Loganzo,et al.  Mild method for succinimide hydrolysis on ADCs: impact on ADC potency, stability, exposure, and efficacy. , 2014, Bioconjugate chemistry.

[20]  C. Bertozzi,et al.  Site-Specific Antibody–Drug Conjugates: The Nexus of Bioorthogonal Chemistry, Protein Engineering, and Drug Development , 2014, Bioconjugate chemistry.

[21]  Bin Liu,et al.  Methods for site-specific drug conjugation to antibodies , 2013, mAbs.

[22]  Chan Hyuk Kim,et al.  Bispecific small molecule–antibody conjugate targeting prostate cancer , 2013, Proceedings of the National Academy of Sciences.

[23]  Paul Polakis,et al.  Site-specific antibody drug conjugates for cancer therapy , 2013, mAbs.

[24]  N. Bander,et al.  Antitumor Activity of MEDI3726 (ADCT-401), a Pyrrolobenzodiazepine Antibody–Drug Conjugate Targeting PSMA, in Preclinical Models of Prostate Cancer , 2018, Molecular Cancer Therapeutics.

[25]  R. Chari,et al.  Ado-trastuzumab Emtansine (T-DM1): an antibody-drug conjugate (ADC) for HER2-positive breast cancer. , 2014, Journal of medicinal chemistry.

[26]  Matthew R. Levengood,et al.  Orthogonal Cysteine Protection Enables Homogeneous Multi‐Drug Antibody–Drug Conjugates , 2016, Angewandte Chemie.

[27]  I. Bernstein,et al.  Gemtuzumab ozogamicin for acute myeloid leukemia. , 2017, Blood.

[28]  Louise Robinson,et al.  Long-term stabilization of maleimide-thiol conjugates. , 2015, Bioconjugate chemistry.

[29]  I. Bernstein,et al.  SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML. , 2013, Blood.

[30]  P. Senter,et al.  The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma , 2012, Nature Biotechnology.

[31]  Xiuling Li,et al.  Site-Specific Dual Antibody Conjugation via Engineered Cysteine and Selenocysteine Residues. , 2015, Bioconjugate chemistry.

[32]  R. Advani,et al.  Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  Wei Huang,et al.  One-pot N-glycosylation remodeling of IgG with non-natural sialylglycopeptides enables glycosite-specific and dual-payload antibody-drug conjugates. , 2016, Organic & biomolecular chemistry.

[34]  M. Follettie,et al.  Tumor Cells Chronically Treated with a Trastuzumab–Maytansinoid Antibody–Drug Conjugate Develop Varied Resistance Mechanisms but Respond to Alternate Treatments , 2015, Molecular Cancer Therapeutics.

[35]  Wei Huang,et al.  Real-Time Analysis on Drug-Antibody Ratio of Antibody-Drug Conjugates for Synthesis, Process Optimization, and Quality Control , 2017, Scientific Reports.

[36]  Pedro M. P. Gois,et al.  Cysteine-selective reactions for antibody conjugation. , 2014, Angewandte Chemie.